Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry

References

• Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO, Al-Katib W, Stitt LW, Uede T, Chambers AF, Tuck AB. (2006). Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169:233–246.
   PubMed Web of Science ®Google Scholar
• Anborgh PH, Wilson SM, Tuck AB, Winquist E, Schmidt N, Hart R, Kon S, Maeda M, Uede T, Stitt LW, Chambers AF. (2009). New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. Clin Chem 55:895–903.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lee JH, Ramaiah SK. (2008). Interaction of osteopontin with neutrophil α(4)β(1) and α(9)β(1) integrins in a rodent model of alcoholic liver disease. Toxicol Appl Pharmacol 233:238–246.
   PubMed Web of Science ®Google Scholar
• Blasberg JD, Goparaju CM, Pass HI, Donington JS. (2010a) Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg 139:1587–1593.
   PubMed Web of Science ®Google Scholar
• Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. (2010b) Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 28:936–941.
   PubMed Web of Science ®Google Scholar
• Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI, Kim KW. (2009). Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol 35:1409–1416.
   PubMed Web of Science ®Google Scholar
• Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. (2007). Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57:373–380.
   PubMed Web of Science ®Google Scholar
• Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT, Sørensen ES. (2007). Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 282:19463–19472.
   PubMed Web of Science ®Google Scholar
• Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sørensen ES. (2005). Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390:285–292.
   PubMed Web of Science ®Google Scholar
• Christensen B, Petersen TE, Sørensen ES. (2008). Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 411:53–61.
   PubMed Web of Science ®Google Scholar
• Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, Koong AC, Giaccia A, Le QT. (2010). The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS ONE 5:e9633.
   PubMed Web of Science ®Google Scholar
• Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW. (2011). Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma–which is best? Lung Cancer 74:55–60.
   PubMed Web of Science ®Google Scholar
• Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS. (2010). Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 5:1516–1523.
   PubMed Web of Science ®Google Scholar
• He B, Mirza M, Weber GF. (2006). An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25:2192–2202.
   PubMed Web of Science ®Google Scholar
• Ivanov SV, Ivanova AV, Goparaju CM, Chen Y, Beck A, Pass HI. (2009). Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun 382:514–518.
   PubMed Web of Science ®Google Scholar
• Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC. (2007). Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 11:81–90.
   PubMed Web of Science ®Google Scholar
• Kazanecki CC, Uzwiak DJ, Denhardt DT. (2007). Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 102:912–924.
   PubMed Web of Science ®Google Scholar
• Keykhosravani M, Doherty-Kirby A, Zhang C, Brewer D, Goldberg HA, Hunter GK, Lajoie G. (2005). Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry. Biochemistry 44:6990–7003.
   PubMed Web of Science ®Google Scholar
• Kiernan UA, Phillips DA, Trenchevska O, Nedelkov D. (2011). Quantitative mass spectrometry evaluation of human retinol binding protein 4 and related variants. PLoS ONE 6:e17282.
   PubMed Web of Science ®Google Scholar
• Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, Sabatine MS, Gerszten RE, Carr SA. (2009). Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 55:1108–1117.
   PubMed Web of Science ®Google Scholar
• Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. (2004). Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 4:1175–1186.
   PubMed Web of Science ®Google Scholar
• Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR; SWOG. (2008). Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26:4771–4776.
   PubMed Web of Science ®Google Scholar
• Makawita S, Diamandis EP. (2010). The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem 56:212–222.
   PubMed Web of Science ®Google Scholar
• Meng Z, Veenstra TD. (2011) Targeted mass spectrometry approaches for protein biomarker verification. J Proteomics 74:2650.
   PubMed Web of Science ®Google Scholar
• Mi Z, Guo H, Wai PY, Gao C, Wei J, Kuo PC. (2004). Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior. J Biol Chem 279:46659–46667.
   PubMed Web of Science ®Google Scholar
• Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF. (2008). Osteopontin-c is a selective marker of breast cancer. Int J Cancer 122:889–897.
   PubMed Web of Science ®Google Scholar
• Nicol GR, Han M, Kim J, Birse CE, Brand E, Nguyen A, Mesri M, FitzHugh W, Kaminker P, Moore PA, Ruben SM, He T. (2008). Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients. Mol Cell Proteomics 7:1974–1982.
   PubMed Web of Science ®Google Scholar
• Ocaña MF, Neubert H. (2010). An immunoaffinity liquid chromatography-tandem mass spectrometry assay for the quantitation of matrix metalloproteinase 9 in mouse serum. Anal Biochem 399:202–210.
   PubMed Web of Science ®Google Scholar
• Paleari L, Rotolo N, Imperatori A, Puzone R, Sessa F, Franzi F, Meacci E, Camplese P, Cesario A, Paganuzzi M. (2009). Osteopontin is not a specific marker in malignant pleural mesothelioma. Int J Biol Markers 24:112–117.
   PubMed Web of Science ®Google Scholar
• Plumer A, Duan H, Subramaniam S, Lucas FL, Miesfeldt S, Ng AK, Liaw L. (2008). Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer. BMC Cancer 8:38.
   PubMed Web of Science ®Google Scholar
• Rangaswami H, Bulbule A, Kundu GC. (2006). Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79–87.
   PubMed Web of Science ®Google Scholar
• Shakey Q, Bates B, Wu J. (2010). An approach to quantifying N-linked glycoproteins by enzyme-catalyzed 18O3-labeling of solid-phase enriched glycopeptides. Anal Chem 82:7722–7728.
   PubMed Web of Science ®Google Scholar
• Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz A, Weber GF, Denhardt DT, Yeo CJ, Arafat HA. (2009). Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 146:232–240.
   PubMed Web of Science ®Google Scholar
• Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, Viola JP, Weber GF, Gimba ER. (2011). Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 9:280–293.
   PubMed Web of Science ®Google Scholar
• Vordermark D, Said HM, Katzer A, Kuhnt T, Hänsgen G, Dunst J, Flentje M, Bache M. (2006). Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 6:207.
   PubMed Web of Science ®Google Scholar
• Wai PY, Kuo PC. (2008). Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27:103–118.
   PubMed Web of Science ®Google Scholar
• Weber GF, Zawaideh S, Hikita S, Kumar VA, Cantor H, Ashkar S. (2002). Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol 72:752–761.
   PubMed Web of Science ®Google Scholar
• Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, Jin Y, Li W. (2011). Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol 137:1061–1070.
   PubMed Web of Science ®Google Scholar